IVBXF — Innovent Biologics Inc/ADR

OTC · Unknown · Unknown · CIK 1774163 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
2026-03-26
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 37,347,839,000 17,344,705,000 17,991,596,000
Jun 2025 23,594,272,000 9,540,139,000 9,172,452,000
Dec 2024 21,602,602,000 7,508,185,000 8,484,873,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-15,092,803,000
Inventory
$1,301,745,000
Receivables
ST Investments
$886,741,000
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$13,041,522,688
EBITDA
$1,310,151,936
Free Cash Flow
$3,228,137,984
Enterprise Value
$1,566,292,736
Total Cash
$18,231,445,504
Total Debt
$2,815,774,976
Shares Out
1,734,623,465
Trailing EPS
$0.07
Book Value
$1.65
ROE
5.0%
ROA
1.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 13,041,523,000 2,140,913,000 813,565,000 37,347,839,000 17,991,596,000 10,001,012,000
Dec 2024 9,421,888,000 258,119,000 -94,631,000 21,602,602,000 8,484,873,000 1,287,024,000
Dec 2023 6,206,070,000 -909,210,000 -1,027,913,000 20,627,360,000 8,099,779,000 147,810,000
Dec 2022 4,556,380,000 -2,581,885,000 -2,179,270,000 17,588,845,000 6,858,896,000 -1,918,804,000

Peers — same industry

TickerNameMarket CapLastDaily %
KLAC KLA CORP $332.50B $254.54
KXIAY Kioxia Holdings Corporation/ADR $288.33B $52.80
IBM INTERNATIONAL BUSINESS MACHINES CORP $255.87B $272.24
TMO THERMO FISHER SCIENTIFIC INC. $174.42B $469.34
SMERY Siemens Energy AG/ADR $150.30B $176.65

News headlines (Yahoo Finance, 1h cache)

Global Value Stocks Trading Below Estimated Worth In June 2026
2026-06-15 09:38 · Yahoo
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 29.4%
2026-06-15 04:38 · Yahoo
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
2026-06-08 08:30 · Yahoo
3 Asian Stocks Estimated To Be Priced Below Intrinsic Value In June 2026
2026-06-05 04:37 · Yahoo
3 Asian Stocks Estimated To Be Up To 43.2% Below Intrinsic Value
2026-06-04 22:34 · Yahoo
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an
2026-06-04 08:35 · Yahoo
Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China
2026-06-03 11:00 · Yahoo
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?
2026-06-02 14:11 · Yahoo
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
2026-06-02 13:58 · Yahoo
Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
2026-06-01 15:11 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.